OWEN KATEY EINTERZ 4

What Happened
Katey Einterz, a director of Adaptive Biotechnologies Corp (ADPT), was granted 15,625 shares on March 4, 2026. The Form 4 reports the acquisition as an award (transaction code A) at an acquisition price of $0, yielding a reported dollar value of $0 on the filing. This was an award/compensation event (not a market purchase or sale).

Key Details

• Transaction date: 2026-03-04
• Transaction type/code: Award/Grant (A)
• Shares acquired: 15,625
• Acquisition price: $0.00 (reported value $0)
• Filing date: 2026-03-06 (Form 4 accession 0001852578-26-000002)
• Shares owned after transaction: not specified in the provided excerpt of the filing
• Footnotes or special instructions: none provided in the excerpt

Context
An award reported at $0 typically reflects a compensation grant (e.g., restricted stock or RSUs) rather than an open-market purchase. Such grants often vest over time and may be subject to restrictions or tax-withholding; the filing excerpt does not list vesting or withholding details. Awards are routine for directors as part of compensation and do not, by themselves, indicate buying or selling sentiment in the market. For full holdings and any vesting/conditions, consult the complete Form 4.